Founded in 2017, CyGenica operates in Health Tech offering non-viral, non-toxic delivery solutions for drugs, gene editing components, and antibiotics. The company focuses on overcoming the cellular m...
Funding stage:
Seed
Last funding:
10/06/2021
Total funding:
$1.40 Mn+
Revenue:
Investors
Employee count:
10
Last 90d
10
Last 90d
Web traffic:
600
600
Last 30d
Last 30d
CyGenica: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders2
Latest Filing Date30 March 2023- Funding Events10
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of CyGenica
As of 31 March 2023, CyGenica's equity is held by 2 shareholders, with the top three being CYGENICA and Nusrat Jahan Mobassarah Sanghamitra.
CYGENICA holds the largest stake in CyGenica at 100.0% as of 31 March 2023.
As of 31 March 2023, founders collectively hold 0.0% equity in CyGenica.
As of 31 March 2023, investors collectively hold 100.0% equity in CyGenica.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links